Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines

Objectives Significant variability in the efficacy and toxicity of an anticancer drug is observed in cancer patients. Currently, there are no standard tools for prediction of a patient's tumor response or his risk of adverse events to chemotherapy. Methods We investigate an association between polymorphisms of gemcitabine metabolism-related genes and its chemosensitivity in vitro using 62 human cancer cell lines of various origins. Polymorphisms of gemcitabine metabolism-related genes of deoxycytidine monophosphate deaminase (DCTD), deoxycytidine kinase (DCK) and ribonucleotide reductase M1 (RRM1) were evaluated using the CEQ8000 Genetic analysis system and GeneDoc software. Chemosensitivity of gemcitabine was expressed as an IC50 using MTT assay. Results The frequency of the polymorphisms was 21% in DCTD 315T>C, 45.2% in RRM1 1082C>A, 59.7% in RRM1 2455A>G, and 79% in RRM1 2464G>A. When examining the association between these polymorphisms and IC50, only the RRM1 2464G>A showed the tendency to be more chemosensitive to gemcitabine (P=0.011), and haplotypes containing 2464G>A polymorphism also showed the association with chemosensitivity when compared to wild-type RRM1 (G2464G). We could not see the significant differences of mRNA expression level with real-time PCR between cell lines according to G2464A polymorphism. In oligonucleotide microarray 73 GenBank Accession Number (69 genes) were selected which expressed differently between RRM1 wild-type and the G2464A polymorphism. Conclusions RRM1 2464G>A polymorphism demonstrated an association with gemcitabine sensitivity, which needs functional studies with co-expressing genes and prospective clinical studies for the clinical application as a predictive bio-marker.

[1]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[2]  A. Roses,et al.  Pharmacogenetics and future drug development and delivery , 2000, The Lancet.

[3]  SUSANA PEREIRA,et al.  Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine , 2004, J. Comput. Chem..

[4]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[5]  J. Mackey,et al.  Nucleoside analogues: mechanisms of drug resistance and reversal strategies , 2001, Leukemia.

[6]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[7]  J. Mackey,et al.  Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line , 2004, Clinical Cancer Research.

[8]  H. McLeod,et al.  Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway , 2004, The Pharmacogenomics Journal.

[9]  G. Nocentini,et al.  Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. , 1996, Critical reviews in oncology/hematology.

[10]  G. Peters,et al.  Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) , 2002 .

[11]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[12]  Yate-Ching Yuan,et al.  In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase , 2004, Cancer Research.

[13]  M. Ratain,et al.  Pharmacogenetics and cancer chemotherapy. , 1998, European journal of cancer.

[14]  Pedro Alexandrino Fernandes,et al.  Ribonucleotide activation by enzyme ribonucleotide reductase: Understanding the role of the enzyme , 2004, Journal of computational chemistry.

[15]  G. Kim,et al.  A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane. , 2002, Cancer research and treatment : official journal of Korean Cancer Association.

[16]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[17]  Michael Wiese,et al.  Comparison of the Usefulness of the MTT, ATP, and Calcein Assays to Predict the Potency of Cytotoxic Agents in Various Human Cancer Cell Lines , 2004, Journal of biomolecular screening.

[18]  S. Marsh,et al.  Cancer pharmacogenetics , 2004, British Journal of Cancer.

[19]  J. Mackey,et al.  Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene , 2004, BMC pharmacology.

[20]  F. Fossella,et al.  Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. , 2002, Lung cancer.

[21]  W. O'brien,et al.  Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase. , 2000, Biochemical Journal.

[22]  D. Shewach,et al.  The role of DNA synthesis inhibition in the cytotoxicity of 2′,2′-difluoro-2′-deoxycytidine , 2003, Cancer Chemotherapy and Pharmacology.

[23]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  W. Evans,et al.  Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.

[25]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[26]  E. Giovannetti,et al.  Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines , 2004, Clinical Cancer Research.

[27]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Yen,et al.  Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. , 1999, Cancer research.

[29]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[30]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[31]  Y. Yen.  Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[33]  G. Peters,et al.  Preclinical combination therapy with gemcitabine and mechanisms of resistance. , 1996, Seminars in oncology.